Related Experiment Videos
[Verify the optimum administration of anticancer agent--cisplatin]
1Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
Summary
Cisplatin is effective against solid cancers. Different administration methods (intra-arterial, intraperitoneal) are explored to enhance effects and reduce side effects, though further trials are needed.
Area of Science:
- Oncology
- Pharmacology
- Cancer Chemotherapy
Context:
- Cisplatin is a cornerstone chemotherapy agent for numerous solid tumors.
- Intra-venous bolus injection is the standard administration route.
- Alternative delivery methods are being investigated to optimize therapeutic outcomes.
Purpose:
- To review the efficacy and side effect profiles of various cisplatin administration routes.
- To compare bolus intra-venous injection with intra-arterial and intraperitoneal chemotherapy.
- To highlight the need for comparative trials to establish optimal cisplatin regimens.
Summary:
- Bolus intra-venous cisplatin commonly causes renal damage.
- Intermittent administration may lead to more severe bone marrow suppression.
- Intra-arterial and intraperitoneal routes show potential for local and systemic effects but require further validation.
- Current evidence supporting these alternative protocols is limited, lacking comparative trial data.
Impact:
- Identifies potential strategies to improve cisplatin therapy for solid cancers.
- Underscores the necessity of rigorous clinical trials to confirm the benefits of alternative cisplatin administration methods.
- Informs future research directions in optimizing cancer chemotherapy delivery.